Skip to content
2000
Volume 18, Issue 1
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Computational drug repositioning has emerged as an efficient approach to discovering new indications for existing drugs, offering lower risk and cost compared to traditional drug discovery methods. Various computational approaches have been developed, including target-based, gene-expression-based, phenome-based, and multi-omics-based methods. Recent advancements leverage diverse data sources, such as biomedical databases and online health-related information. Techniques incorporating drug structure and target information have shown promising results in predicting new drug indications. Despite significant progress, challenges remain, including data noise reduction, method ensemble, negative sample selection, and data sparseness. Overall, computational drug repositioning continues to be a valuable tool in drug discovery and development.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775365699250408091801
2025-04-21
2026-02-24

  • From This Site

    /content/journals/cdrr/10.2174/0125899775365699250408091801
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HuangG. LiJ. WangP. LiW. A review of computational drug repositioning approaches.Comb. Chem. High Throughput Screen.2018201083183810.2174/1386207321666171221112835 29268682
     [Google Scholar]
  2. JourdanJ.P. BureauR. RochaisC. DallemagneP. Drug repositioning: A brief overview.J. Pharm. Pharmacol.20207291145115110.1111/jphp.13273 32301512
     [Google Scholar]
  3. NosengoN. New tricks for old drugs: Faced with skyrocketing costs for developing new drugs, researchers are looking at ways to repurpose older ones-and even some that failed in initial trials.Nature2016534760731431710.1038/534314a 27306171
     [Google Scholar]
  4. Drug Discov World.2014Available from: line.com/drug-discovery/p274232-therapeutic-drug-repurposingrepositioning-and-rescue-part-i:-overview. html
  5. CavallaD. Scientific and commercial value of drug repurposing.In: Drug Repositioning.Boca Raton, FL, USACRC Press201732210.4324/9781315373669‑1
     [Google Scholar]
  6. NovacN. Challenges and opportunities of drug repositioning.Trends Pharmacol. Sci.201334526727210.1016/j.tips.2013.03.004 23582281
     [Google Scholar]
  7. SahuN.U. KharkarP.S. Computational drug repositioning: A lateral approach to traditional drug discovery?Curr. Top. Med. Chem.201616192069207710.2174/1568026616666160216153249 26881717
     [Google Scholar]
  8. LuoH. LiM. WangS. LiuQ. LiY. WangJ. Computational drug repositioning using low-rank matrix approximation and randomized algorithms.Bioinformatics201834111904191210.1093/bioinformatics/bty013 29365057
     [Google Scholar]
  9. VogrincD. KunejT. Drug repositioning: Computational approaches and research examples classified according to the evidence level.Discoveries201752e7510.15190/d.2017.5 32309593
     [Google Scholar]
  10. LuoH. LiM. YangM. WuF.X. LiY. WangJ. Biomedical data and computational models for drug repositioning: A comprehensive review.Brief. Bioinform.20212221604161910.1093/bib/bbz176 32043521
     [Google Scholar]
  11. NapolitanoF. ZhaoY. MoreiraV.M. Drug repositioning: A machine-learning approach through data integration.J. Cheminform.2013513010.1186/1758‑2946‑5‑30 23800010
     [Google Scholar]
  12. LiJ. LuZ. A new method for computational drug repositioning using drug pairwise similarity.2012 IEEE International Conference on Bioinformatics and Biomedicine.Philadelphia, PA, USA04-07 October 20121410.1109/BIBM.2012.6392722
     [Google Scholar]
  13. March-VilaE. PinziL. SturmN. On the integration of in silico drug design methods for drug repurposing.Front. Pharmacol.2017829810.3389/fphar.2017.00298 28588497
     [Google Scholar]
  14. YellaJ.K. YaddanapudiS. WangY. JeggaA.G. Changing trends in computational drug repositioning.Pharmaceuticals20181125710.3390/ph11020057 29874824
     [Google Scholar]
  15. ScannellJ.W. BlanckleyA. BoldonH. WarringtonB. Diagnosing the decline in pharmaceutical R&D efficiency.Nat. Rev. Drug Discov.201211319120010.1038/nrd3681 22378269
     [Google Scholar]
  16. MichienziA. TobarranN. HiegerM.A. Extended release acetaminophen overdose with delayed peak concentrations.Am. J. Ther.2022296e655e65610.1097/MJT.0000000000001329 33491964
     [Google Scholar]
  17. GautretP. LagierJ.C. ParolaP. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial.Int. J. Antimicrob. Agents202056110594910.1016/j.ijantimicag.2020.105949 32205204
     [Google Scholar]
  18. BeigelJ.H. TomashekK.M. DoddL.E. Remdesivir for the treatment of Covid-19—preliminary report.N. Engl. J. Med.2020383191813182610.1056/NEJMoa2007764 32445440
     [Google Scholar]
  19. De CaterinaR. AimoA. RidkerP.M. Aspirin therapy for primary prevention: The case for continuing prescribing to patients at high cardiovascular risk—A review.Thromb. Haemost.2020120219920610.1055/s‑0039‑3400294 31887781
     [Google Scholar]
  20. TardifJ.C. BouabdallaouiN. L’AllierP.L. Colchicine for community-treated patients with COVID-19 (COLCORONA): A phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.Lancet Respir. Med.20219892493210.1016/S2213‑2600(21)00222‑8 34051877
     [Google Scholar]
  21. LiuY. YanL.M. WanL. Viral dynamics in mild and severe cases of COVID-19.Lancet Infect. Dis.202020665665710.1016/S1473‑3099(20)30232‑2 32199493
     [Google Scholar]
  22. SaengboonmeeC. SanlungT. WongkhamS. Repurposing metformin for cancer treatment: A great challenge of a promising drug.Anticancer Res.202141125913591810.21873/anticanres.15410 34848445
     [Google Scholar]
  23. LokhandeA.S. DevarajanP.V. A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.Eur. J. Pharmacol.202189117374810.1016/j.ejphar.2020.173748 33227285
     [Google Scholar]
  24. KastritisE. DimopoulosM.A. Thalidomide in the treatment of multiple myeloma.Best Pract. Res. Clin. Haematol.200720468169910.1016/j.beha.2007.09.001 18070713
     [Google Scholar]
  25. MalekA.E. GranwehrB.P. KontoyiannisD.P. Doxycycline as a potential partner of COVID-19 therapies.IDCases202021e0086410.1016/j.idcr.2020.e00864 32566483
     [Google Scholar]
  26. AshburnT.T. ThorK.B. Drug repositioning: Identifying and developing new uses for existing drugs.Nat. Rev. Drug Discov.20043867368310.1038/nrd1468 15286734
     [Google Scholar]
  27. LiQ. ChengT. WangY. BryantS.H. PubChem as a public resource for drug discovery.Drug Discov. Today20101523-241052105710.1016/j.drudis.2010.10.003
     [Google Scholar]
  28. GaultonA. HerseyA. NowotkaM. The ChEMBL database in 2017.Nucleic Acids Res.201745D1D945D95410.1093/nar/gkw1074 27899562
     [Google Scholar]
  29. WishartD.S. FeunangY.D. GuoA.C. DrugBank 5.0: A major update to the DrugBank database for 2018.Nucleic Acids Res.201846D1D1074D108210.1093/nar/gkx1037 29126136
     [Google Scholar]
  30. ZhaoC. DaiX. LiY. EK-DRD: A comprehensive database for drug repositioning inspired by experimental knowledge.J. Chem. Inf. Model.20195993619362410.1021/acs.jcim.9b00365 31433187
     [Google Scholar]
  31. DavisA.P. GrondinC.J. JohnsonR.J. The comparative toxicogenomics database: Update 2017.Nucleic Acids Res.201745D1D972D97810.1093/nar/gkw838 27651457
     [Google Scholar]
  32. BatemanA. MartinM-J. OrchardS. UniProt: The universal protein knowledgebase in 2021.Nucleic Acids Res.202149D1D480D48910.1093/nar/gkaa1100 33237286
     [Google Scholar]
  33. AshburnerM. BallC.A. BlakeJ.A. Gene Ontology: Tool for the unification of biology.Nat. Genet.2000251252910.1038/75556 10802651
     [Google Scholar]
  34. KanehisaM. FurumichiM. SatoY. Ishiguro-WatanabeM. TanabeM. KEGG: Integrating viruses and cellular organisms.Nucleic Acids Res.202149D1D545D55110.1093/nar/gkaa970 33125081
     [Google Scholar]
  35. JassalB. MatthewsL. ViteriG. The reactome pathway knowledgebase.Nucleic Acids Res.202048D1D498D503 31691815
     [Google Scholar]
  36. PiñeroJ. BravoÀ. Queralt-RosinachN. DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants.Nucleic Acids Res.2016gkw943 27924018
     [Google Scholar]
  37. BarrettT. EdgarR. Mining microarray data at NCBI’s Gene Expression Omnibus (GEO).Methods Mol. Biol.2006338175190
     [Google Scholar]
  38. SolomonB.D. NguyenA.D. BearK.A. WolfsbergT.G. Clinical genomic database.Proc. Natl. Acad. Sci. USA2013110249851985510.1073/pnas.1302575110 23696674
     [Google Scholar]
  39. WangZ. JensenM.A. ZenklusenJ.C. A practical guide to the cancer genome atlas (TCGA).Methods Mol. Biol.20161418111141
     [Google Scholar]
  40. KulikovaT. AldebertP. AlthorpeN. The EMBL nucleotide sequence database.Nucleic Acids Res.20043290001Suppl. 127D3010.1093/nar/gkh120 14681351
     [Google Scholar]
  41. JensenLJ KuhnM StarkM STRING 8-A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res200937(Database)(Suppl. 1): D412-610.1093/nar/gkn760 18940858
     [Google Scholar]
  42. DigreA. LindskogC. The human protein atlas-Integrated omics for single cell mapping of the human proteome.Protein Sci.2023322e456210.1002/pro.4562 36604173
     [Google Scholar]
  43. AnkenyR.A. Geneticization in MIM/OMIM®? Exploring historic and epistemic drivers of contemporary understandings of genetic disease.J. Med. Philos.201742436738410.1093/jmp/jhx013 28641396
     [Google Scholar]
  44. RomãoP. SouzaÍ.C. SilvaI. Additional activation of the AR gene may be involved in the development of the castration resistance phenotype in prostate cancer.Actas Urol. Esp.2022462788410.1016/j.acuroe.2021.10.003 35123885
     [Google Scholar]
  45. SchuffenhauerA. FloersheimP. AcklinP. JacobyE. Similarity metrics for ligands reflecting the similarity of the target proteins.J. Chem. Inf. Comput. Sci.200343239140510.1021/ci025569t 12653501
     [Google Scholar]
  46. DrugRepurposing Online2025Available from: http://drugrepurposing.info
  47. HuangY. DongD. ZhangW. DrugRepoBank: A comprehensive database and discovery platform for accelerating drug repositioning.Database20242024baae05110.1093/database/baae051 38994794
     [Google Scholar]
  48. The Drug Repurposing Hub.2025Available from: https://repo-hub.broadinstitute.org/repurposing#home
  49. CorselloS.M. BittkerJ.A. LiuZ. The Drug Repurposing Hub: A next-generation drug library and information resource.Nat. Med.201723440540810.1038/nm.4306 28388612
     [Google Scholar]
  50. ChiangA.P. ButteA.J. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses.Clin. Pharmacol. Ther.200986550751010.1038/clpt.2009.103 19571805
     [Google Scholar]
  51. BleakleyK. YamanishiY. Supervised prediction of drug–target interactions using bipartite local models.Bioinformatics200925182397240310.1093/bioinformatics/btp433 19605421
     [Google Scholar]
  52. WangY.C. ZhangC.H. DengN.Y. WangY. Kernel-based data fusion improves the drug–protein interaction prediction.Comput. Biol. Chem.201135635336210.1016/j.compbiolchem.2011.10.003 22099632
     [Google Scholar]
  53. KuangQ. LiY. WuY. A kernel matrix dimension reduction method for predicting drug-target interaction.Chemom. Intell. Lab. Syst.201716210411010.1016/j.chemolab.2017.01.016
     [Google Scholar]
  54. VermaJ.P. VermaJ.P. Logistic regression: Developing a model for risk analysis.Data Analysis in Management with SPSS Software2013413442
     [Google Scholar]
  55. LuK. Logistic regression in biomedical study2022 International Conference on Biotechnology, Life Science and Medical Engineering (BLSME 2022)
     [Google Scholar]
  56. ZaborE.C. ReddyC.A. TendulkarR.D. PatilS. Logistic regression in clinical studies.Int. J. Radiat. Oncol. Biol. Phys.2022112227127710.1016/j.ijrobp.2021.08.007
     [Google Scholar]
  57. CawleyGC TalbotNL Efficient model selection for kernel logistic regression.10.1109/ICPR.2004.1334249
     [Google Scholar]
  58. KoY. Computational drug repositioning: Current progress and challenges.Appl. Sci.20201015507610.3390/app10155076
     [Google Scholar]
  59. FriesnerR.A. BanksJ.L. MurphyR.B. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.J. Med. Chem.20044771739174910.1021/jm0306430 15027865
     [Google Scholar]
  60. BuckleyM. GjyshiA. Mendoza-FandiñoG. Enhancer scanning to locate regulatory regions in genomic loci.Nat. Protoc.2016111466010.1038/nprot.2015.136 26658467
     [Google Scholar]
  61. LiH GaoZ KangL TarFisDock: A web server for identifying drug targets with docking approach.Nucleic Acids Res200634(Web Server)(Suppl. 2): W219-24.10.1093/nar/gkl114 16844997
     [Google Scholar]
  62. CheeserightT. MackeyM. RoseS. VinterA. Molecular field extrema as descriptors of biological activity: Definition and validation.J. Chem. Inf. Model.200646266567610.1021/ci050357s 16562997
     [Google Scholar]
  63. ShermanW. BeardH.S. FaridR. Use of an induced fit receptor structure in virtual screening.Chem. Biol. Drug Des.2006671838410.1111/j.1747‑0285.2005.00327.x 16492153
     [Google Scholar]
  64. HalgrenT. New method for fast and accurate binding-site identification and analysis.Chem. Biol. Drug Des.200769214614810.1111/j.1747‑0285.2007.00483.x 17381729
     [Google Scholar]
  65. TianW. ChenC. LiangJ. CASTp 3.0: Computed atlas of surface topography of proteins and beyond.Biophys. J.2018114350a10.1016/j.bpj.2017.11.325
     [Google Scholar]
  66. SkolnickJ. BrylinskiM. FINDSITE: A combined evolution/structure-based approach to protein function prediction.Brief. Bioinform.200910437839110.1093/bib/bbp017 19324930
     [Google Scholar]
  67. Anaxomics, Therapeutic Performance Mapping System (TPMS).2024Available from: http://www.anaxomics.com/tpms. php
  68. CheeserightT.J. MackeyM.D. MelvilleJ.L. VinterJ.G. FieldScreen: Virtual screening using molecular fields. Application to the DUD data set.J. Chem. Inf. Model.200848112108211710.1021/ci800110p 18991371
     [Google Scholar]
  69. DainaA. MichielinO. ZoeteV. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.Sci. Rep.2017714271710.1038/srep42717 28256516
     [Google Scholar]
  70. WelterD. MacArthurJ. MoralesJ. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.Nucleic Acids Res.201442D1D1001D100610.1093/nar/gkt1229 24316577
     [Google Scholar]
  71. LambJ. CrawfordE.D. PeckD. The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease.Science2006313579519291935
     [Google Scholar]
  72. PowersD.M. Evaluation: From precision, recall and F-measure to ROC, informedness, markedness and correlation arXiv:2010160612020
  73. BradleyA.P. The use of the area under the ROC curve in the evaluation of machine learning algorithms.Pattern Recognit.19973071145115910.1016/S0031‑3203(96)00142‑2
     [Google Scholar]
  74. DavisJ. GoadrichM. The relationship between Precision-Recall and ROC curves.Proceedings of the 23rd international conference on Machine learningPittsburgh, Pennsylvania, USA200623324010.1145/1143844.1143874
     [Google Scholar]
  75. ChristopherD.M. PrabhakarR. HinrichS. Introduction to information retrieval.Cambridge, EnglandCambridge University Press2008
     [Google Scholar]
  76. TruchonJ.F. BaylyC.I. Evaluating virtual screening methods: Good and bad metrics for the “early recognition” problem.J. Chem. Inf. Model.200747248850810.1021/ci600426e 17288412
     [Google Scholar]
  77. IrwinJ.J. ShoichetB.K. ZINC-A free database of commercially available compounds for virtual screening.J. Chem. Inf. Model.200545117718210.1021/ci049714+ 15667143
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775365699250408091801
Loading
Repositioning Drugs: A Computational Approach
Current Drug Research Reviews 18, 62 (2026); https://doi.org/10.2174/0125899775365699250408091801
/content/journals/cdrr/10.2174/0125899775365699250408091801
/content/journals/cdrr/10.2174/0125899775365699250408091801
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biomedical databases; computational approaches; data sources; drug discovery and development; Drug repositioning; noise reduction

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test